Clear dose-response observed, with a robust and clinically meaningful fetal hemoglobin (HbF) induction at the Week 6 timepoint (n=12): mean ...

Fulcrum Therapeutics used its presentation at ASH for its sickle cell disease drug as a springboard for raising US$175m from a one-day marketed follow-on, a more modest (than Terns) 16.7% upsize from ...

Clear dose-response observed, with a robust and clinically meaningful fetal hemoglobin (HbF) induction at the Week 6 timepoint (n=12): mean absolute HbF in the 20 mg cohort increased by 9.9% at Week 6 ...

Piper Sandler boosted its target price to $23 per share from $16. ・Wainwright increased its price target to $25 from $18, ...

Experts call for consistent, specialist care throughout life to prevent complications and improve outcomes for people with ...

Cellarity, a clinical-stage biotechnology company developing Cell State-Correcting therapies through integrated multi-omics and AI modeling, today announced the presentation of new preclinical data on ...

Researchers at the University of Cincinnati presented findings on treatments for blood cancers at a hematology event.

University of Cincinnati researchers will present research at the 67th American Society of Hematology (ASH) Annual Meeting and Exposition Dec. 6-9 in Orlando.

Adding erythropoietin to hydroxyurea treatment could significantly improve quality of life for patients with sickle cell ...

The $10 billion Nigeria LNG Limited Train-7 gas project, is progressively advancing towards completion phase as contractors ...

Shanling’s new SCD3.3 isn’t another nostalgia-driven disc spinner—it’s a purpose-built SACD machine with modern engineering, a full-blown R2R DAC, and a tube output stage baked in. At 10kg, it’s a ...

ReAlta Life Sciences, Inc. ("ReAlta" or the "Company"), a clinical-stage biopharmaceutical company dedicated to saving lives by rebalancing the inflammatory response to address rare and acute ...